Shortages of drugs, particularly those used in chemotherapy, as well as antibiotics, antiepileptics and anesthetics, have become increasingly common, unpredictable and widespread in Canada. These shortages result in poorer health for Canadians, with consequences such as worsening of medical conditions, negative reactions to substitute drugs, cancellation of surgeries and procedures, and increased costs to patients and the health care system.
"It is ridiculous and intolerable that a wealthy, developed nation like Canada cannot reliably provide medicines to its people," write Dr. Matthew Stanbrook, Deputy Editor, CMAJ, and Rosemary Killeen, Editor-in-Chief, CPJ.
"Although the causes of drug shortages are myriad and complex, Canada's lack of preparedness for and ability to cope with this problem seem more readily apparent," the authors write. "One salient feature is the absence of integrated, coordinated national leadership on drug policy in Canada."
Europe and the United States require pharmaceutical companies to inform governments in advance of possible drug shortages. Canada, however, is relying on industry to establish a voluntary reporting system rather than establishing a mandatory reporting system.
"A mandatory reporting system for impending shortages should be created and maintained, so that health care stakeholders at all levels have adequate and timely information with which to make decisions," state the authors.
With national leadership to manage the issue, Canada could take other steps to minimize the effect of shortages, including:
"The people of Canada deserve greater responsiveness and action from their elected officials to safeguard the supply of some of the most critical components of health care delivery," the authors conclude.
Advertise with us - Download World Pharma News' Media Pack Read more
August marks National Psoriasis Awareness Month, an opportunity to raise awareness about psoriasis, a skin disease that affects nearly 7.5 million Americans. For those living with this condition, finding information Read more
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, Read more
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in Read more
Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving Read more
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better Read more
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: Read more
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 Read more
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth Read more